Masitinib (4.5) — Competitive Intelligence Brief

Masitinib (4.5) (Masitinib (4.5)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tyrosine kinase inhibitor. Area: Oncology, Immunology, Neurology.

phase 3 Tyrosine kinase inhibitor c-KIT, PDGFR, Lyn Oncology, Immunology, Neurology Small molecule

Target snapshot

Masitinib (4.5) (Masitinib (4.5)) — AB Science. Masitinib is a tyrosine kinase inhibitor that selectively targets c-KIT, PDGFR, and Lyn kinases to modulate immune cell function and reduce pathological inflammation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Masitinib (4.5) TARGET	Masitinib (4.5)	AB Science	phase 3	Tyrosine kinase inhibitor	c-KIT, PDGFR, Lyn
Inlyta	Axitinib	Pfizer	marketed	Receptor tyrosine kinase inhibitor	Vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, VEGFR-3	2012-01-01
Sunitinib Malate (SU011248)	Sunitinib Malate (SU011248)	H. Lee Moffitt Cancer Center and Research Institute	marketed	Multi-targeted tyrosine kinase inhibitor	VEGFR, PDGFR, KIT, FLT3
Lenvatinib + losartan	Lenvatinib + losartan	Second Affiliated Hospital of Xi'an Jiaotong University	marketed	Multi-targeted tyrosine kinase inhibitor + angiotensin II receptor antagonist	FGFR, VEGFR, RET (lenvatinib); AT1 receptor (losartan)
Erlotinib, Pemetrexed	Erlotinib, Pemetrexed	Hunan Province Tumor Hospital	marketed	EGFR tyrosine kinase inhibitor + antifolate antimetabolite	EGFR; thymidylate synthase and folate-dependent enzymes
Icotinib plus WBRT	Icotinib plus WBRT	Betta Pharmaceuticals Co., Ltd.	marketed	EGFR tyrosine kinase inhibitor	EGFR (epidermal growth factor receptor)
Letybo®	Letybo®	Yuvell	marketed	FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor	FLT3, JAK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tyrosine kinase inhibitor class)

1. Jiangsu HengRui Medicine Co., Ltd. · 5 drugs in this class
2. Centre Leon Berard · 2 drugs in this class
3. AB Science · 2 drugs in this class
4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 2 drugs in this class
5. Betta Pharmaceuticals Co., Ltd. · 1 drug in this class
6. Angion Biomedica Corp · 1 drug in this class
7. Beijing InnoCare Pharma Tech Co., Ltd. · 1 drug in this class
8. Chang-Ming Huang, Prof. · 1 drug in this class
9. Deciphera Pharmaceuticals, LLC · 1 drug in this class
10. AstraZeneca · 1 drug in this class